MDPI
MDPI is pleased to announce the opening of nominations for the 2024 Tu Youyou Award, a prestigious recognition established in honor of Professor Tu Youyou, Nobel Laureate, whose discovery has significantly altered the global fight against Malaria.
The Tu Youyou Award offers CHF 100,000
In 2015, Professor Tu Youyou was awarded the Nobel Prize in Physiology or Medicine for her discovery of artemisinin, significantly reducing mortality rates from malaria and shaping global health policies. Artemisinin-based combination therapies (ACTs) are now the standard treatment endorsed by the World Health Organization (WHO). This groundbreaking work has saved countless lives, especially in regions heavily burdened by Malaria.
To mark Professor Tu's 80th birthday in 2009, MDPI's journal Molecules issued a Special Issue focusing on her contributions to medical research. Recognizing her continuous contribution, MDPI created the Tu Youyou Award in 2016 to honor outstanding achievements in natural products and medicinal chemistry.
The deadline for nominations is 31 December 2024
The Tu Youyou Award offers CHF 100,000, split equally among winners. Nominations are open to scientists excelling in natural products and medicinal chemistry. Eligible nominators include academic institutes, universities, and societies. Nominations close on 31 December 2024, with winners announced on 30 April 2025.
MDPI encourages the academic community to nominate individuals who have demonstrated excellence and innovation akin to Professor Tu’s legacy. This award not only honors individual achievement but also encourages further scientific exploration and discovery in critical areas of medicine.
Stefan Tochev, CEO of MDPI, said, “This award truly embodies our deep commitment to groundbreaking research that drives societal progress and celebrates the legacy of one of the greatest medical innovators of our time.”
For more information, please visit MDPI’s official website or the dedicated Tu Youyou Award page.
About MDPI
MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6000 diligent, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 445 fully OA titles.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240705939770/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Launches Tariff Response Solution to Help Supply Chains Adapt to Disruption with Confidence17.4.2025 19:30:00 CEST | Press release
New solution simulates tariff impacts, aligns teams, and enables action in under three weeks As ongoing tariff pressures and trade uncertainty continue to reshape global supply chains, Kinaxis® (TSX:KXS), the leader in real-time supply chain orchestration, today launched Kinaxis Tariff Response - a new offering that helps companies simulate tariff exposure, run strategic scenarios, and make data-informed decisions quickly. Built on the company’s AI-powered Maestro™ platform and delivered by Kinaxis supply chain experts, the service can be live in as few as 21 days, giving planners access to tariff modeling without the cost or complexity of building it internally. The solution meets rising demand for scenario planning - providing a faster, more accessible way for companies to shift from reactive firefighting to proactive orchestration. While AI-powered what-if scenario planning has long been a core capability of Maestro, Kinaxis Tariff Response builds on that foundation with a focused s
Rigaku and SPERA PHARMA Initiate Strategic Partnership to Advanced Pharmaceutical Development17.4.2025 17:00:00 CEST | Press release
Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”), and SPERA PHARMA, Inc. (headquarters: Osaka; President & Representative Director: Keitaro Iwaki; hereinafter “SPERA PHARMA”) have initiated a strategic partnership aimed at accelerating and transforming pharmaceutical development by leveraging the two companies’ cutting-edge technologies and extensive expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417047994/en/ Left: Keitaro Iwaki, President & Representative Director, SPERA PHARMA; Right: Jun Kawakami, President & CEO, Rigaku SPERA PHARMA will use XtaLAB Synergy-ED, an integrated platform for electronic diffraction provided by Rigaku, for contract analytical services, thereby offering customers robust support in pharmaceutical development. The XtaLAB Synergy-ED incorporates 3D ED/MicroED1, which is utilized for the structu
CORRECTING and REPLACING MultiSafepay Supporting 20,000 SMEs to Scale Through Payment Integration and Digitisation with Antom Technology Engine17.4.2025 15:36:00 CEST | Press release
MultiSafepay, the Amsterdam-based digital payment provider, now serves 20,000+ SME merchants across Europe, with merchant numbers growing 11% since its strategic integration with Antom, empowering thousands of businesses to thrive. Transaction volumes have surged, growing by 44% YoY, driven organically by rapid deployment of POS solutions and collaboration with Antom. Ant International has opened a new office in Amsterdam’s City Centre for MultiSafepay which enables more efficient collaboration with Ant International’s other business pillars. Seventh paragraph, first sentence should read: Today, 8% of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technology (such as C-TAP terminals) as well as Smart POS devices which offer merchants digital tools and do more than just accept payments. (instead of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technolo
MultiSafepay Supporting 20,000 SMEs to Scale Through Payment Integration and Digitisation with Antom Technology Engine17.4.2025 15:36:00 CEST | Press release
MultiSafepay, the Amsterdam-based digital payment provider, now serves 20,000+ SME merchants across Europe, with merchant numbers growing 11% since its strategic integration with Antom, empowering thousands of businesses to thrive. Transaction volumes have surged, growing by 44% YoY, driven organically by rapid deployment of POS solutions and collaboration with Antom. Ant International has opened a new office in Amsterdam’s City Centre for MultiSafepay which enables more efficient collaboration with Ant International’s other business pillars. MultiSafepay (MSP), an Amsterdam-based payment service provider, which became part of Ant International’s Antom, reported strong growth since its strategic integration with Antom, supporting thousands more SMEs in Europe to scale through innovative solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417858076/en/ Ant International’s new office in Amsterdam City Centre will hous
Avania Strengthens Leadership Team With Pivotal Executive Appointments17.4.2025 15:00:00 CEST | Press release
Avania — the leading global MedTech advisory and clinical development partner — today announced the appointments of Jasmine Saba as sr. vice president of strategic relationships and Josh Blacker as sr. vice president of global business development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417247152/en/ Jasmine Saba (left) has been appointed Sr. Vice President of Strategic Relationships. Josh Blacker (right) joins Avania as Sr. Vice President of Global Business Development. Saba Appointed Sr. Vice President of Strategic Relationships Saba will take on this new role to support Avania’s growth by identifying, building, and nurturing key partnerships with global multinational medical technology companies. She will develop repeatable and scalable solutions leveraging Avania’s partnership approach as these customers increasingly rely on Avania to be an extension of their existing teams. With her extensive experience in R&
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom